1,649 results match your criteria: "Pruritus and Systemic Disease"
Anal pruritus: Don't look away.
World J Gastrointest Endosc
March 2024
Department of Gastroenterology, Fernando Pessoa Teaching Hospital, Gondomar, Porto 4420-096, Portugal.
Article Synopsis
- * It can be caused by a variety of factors, including anorectal diseases, infections, and systemic illnesses, and a proper examination is necessary to identify underlying issues.
- * Treatment typically involves maintaining hygiene, avoiding irritants, and using topical therapies like steroids or capsaicin; colonoscopies can help evaluate the condition and guide treatment options.
Article Synopsis
- * The main treatment for AD focuses on proper skin care, including daily baths and the use of moisturizers, along with potentially requiring topical medications like corticosteroids.
- * For severe cases, systemic treatments may be necessary, and it's important for the PCP to monitor for medication side effects and complications like infections, as untreated AD can significantly affect a child's quality of life.
A case of generalized eosinophilic pustular folliculitis: treatment with JAK inhibitor.
J Dermatolog Treat
December 2024
Hospital for Skin Diseases, Shandong First Medical University, Jinan, Shandong, China.
Article Synopsis
- The case study investigates the effectiveness and safety of a Janus kinase (JAK) inhibitor for treating generalized eosinophilic pustular folliculitis (EPF) in a 16-year-old patient who did not respond to traditional treatments.
- The patient was initially treated with oral tofacitinib, resulting in significant symptom relief, but a relapse occurred when the dosage was reduced.
- A switch to the more selective JAK1 inhibitor upadacitinib led to complete recovery, suggesting that JAK inhibitors could be a viable option for EPF patients resistant to standard therapies.
Increased Systemic Levels of Centrally Acting B-Type Natriuretic Peptide Are Associated with Chronic Itch of Different Types.
J Invest Dermatol
October 2024
Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, Miami Itch Center, Miller School of Medicine, University of Miami, Miami, Florida, USA. Electronic address:
Article Synopsis
- B-type natriuretic peptide (BNP) is a neuropeptide associated with various types of itch, showing elevated levels in patients undergoing hemodialysis.
- A study evaluated BNP and N-terminal pro-BNP levels in patients with chronic itch and found a correlation between these levels and itch severity, particularly in those with chronic pruritus of unknown origin.
- Experiments in mice confirmed that increased BNP levels lead to significant scratching, supporting the idea that BNP could play a central role in itch signaling in the spinal cord.
Prurigo: review of its pathogenesis, diagnosis, and treatment.
An Bras Dermatol
August 2024
Department of Infectious Diseases, Dermatology, Imaging Diagnosis and Radiotherapy, Faculty of Medicine, Universidade Estadual Paulista, Botucatu, SP, Brazil.
Article Synopsis
- - Prurigo is a skin condition that causes itchy papules, plaques, and nodules, classified into acute/subacute and chronic types, with various clinical forms and causes.
- - Chronic prurigo shares immunological traits with atopic dermatitis, involving cytokines like IL-4 and IL-31, and requires accurate diagnosis to differentiate from similar skin conditions for effective treatment.
- - Treatments range from antihistamines and topical steroids to more advanced options like dupilumab and JAK inhibitors, which can improve quality of life but may have side effects, particularly in older patients.
Co-occurrence of Idiopathic Hypereosinophilic Syndrome in End-Stage Renal Disease Patients Undergoing Maintenance Hemodialysis.
Cureus
February 2024
Anesthesiology and Critical Care, Duke University Medical Center, Durham, USA.
Article Synopsis
- - Hypereosinophilic syndrome (HES) is characterized by high eosinophil levels in the blood, organ damage from eosinophils, and the exclusion of other causes for these symptoms.
- - This report discusses two end-stage renal disease patients on hemodialysis who developed HES, presenting symptoms such as itching and low blood pressure during dialysis sessions.
- - Both patients improved with steroid treatment, highlighting the need for awareness of HES in dialysis patients and the ongoing uncertainty regarding the best treatment approach.
Janus kinase inhibitors in atopic dermatitis: an umbrella review of meta-analyses.
Front Immunol
March 2024
Dermatological Department, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Article Synopsis
- Clinicians are facing an influx of meta-analyses (MAs) regarding Janus kinase inhibitors (JKIs) for treating atopic dermatitis (AD), highlighting a need for clear and comprehensive evidence on their effectiveness and safety.
- Sixteen MAs were reviewed, revealing that JKIs lead to a quicker response in terms of overall assessment (IGA) and significant improvements in eczema severity (EASI75), with most studies showing high-quality evidence for their efficacy.
- While JKIs were generally safe, specific doses of abrocitinib showed increased risks for side effects like acne and headaches, indicating a need for careful monitoring and choice in treatment.
Concurrent nivolumab and external beam radiation therapy for hepatocellular carcinoma with macrovascular invasion: A phase II study.
JHEP Rep
April 2024
Center for Liver and Pancreatobiliary Cancer, National Cancer Center, Goyang, Republic of Korea.
Article Synopsis
- Nivolumab, an immune checkpoint inhibitor, was tested alongside external beam radiation therapy (EBRT) for treating hepatocellular carcinoma (HCC) with macrovascular invasion, aiming to evaluate its efficacy and safety.* -
- In a phase II trial involving 50 patients, the median progression-free survival (PFS) was 5.6 months, and overall survival was 15.2 months, with an objective response rate of 36% and a disease control rate of 74% observed.* -
- While 80% of patients experienced treatment-related side effects, mostly mild (like pruritus and rash), the combination therapy demonstrated promising results, indicating that it can be a viable option for managing this type
An occurrence of eosinophilic folliculitis and alopecia associated with a sustained complete response to mogamulizumab in Sézary syndrome: a case report.
Ther Adv Hematol
March 2024
Department of Dermatology, Caen-Normandie University Hospital, Avenue de la Côte de Nacre, 14003 Caen, France.
Article Synopsis
- Mogamulizumab is a monoclonal antibody that targets CCR4, effective in treating cutaneous T-cell lymphoma like mycosis fungoides and Sézary syndrome, particularly in patients who haven't responded to prior treatments.
- Adverse effects include rash, which can resemble disease progression but may indicate better treatment outcomes in some cases, especially in Sézary syndrome.
- A case of a 72-year-old woman showed a complete response to mogamulizumab despite developing eosinophilic folliculitis and lymphopenia, highlighting the need for careful monitoring and further studies on treatment effects.
Study Design of a Phase 2/3 Randomized Controlled Trial of Dupilumab in Adults with Bullous Pemphigoid: LIBERTY-BP ADEPT.
Adv Ther
July 2024
Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA.
Article Synopsis
- Bullous pemphigoid (BP) is a rare autoimmune skin disease causing significant suffering and reduced quality of life, currently managed with corticosteroids and immunosuppressants that have unwanted side effects.
- A clinical trial named LIBERTY-BP ADEPT is underway to investigate the effectiveness and safety of dupilumab, a drug that targets type 2 inflammation, in treating adults with moderate-to-severe BP.
- The trial includes a 52-week treatment period for 98 adults, focusing on achieving steroid-free remission and other key outcomes such as itch reduction and disease severity over time.
Adverse Reactions After Intradermal Vaccination With JYNNEOS for Mpox in Korea.
J Korean Med Sci
March 2024
Division of Infectious Diseases, Department of Internal Medicine, National Medical Center, Seoul, Korea.
Article Synopsis
- South Korea launched a vaccination program in May 2023 using the JYNNEOS vaccine to combat a domestic Mpox outbreak, targeting high-risk individuals.
- An anonymous online survey conducted from May 22 to July 31, 2023, gathered responses from 142 participants regarding vaccine side effects.
- The majority reported mild local reactions like itching, redness, and swelling, with systemic symptoms like fatigue being less common; overall, the vaccine was found to be well tolerated.
Effectiveness of Narrowband Ultraviolet Light in Chronic Kidney Disease-Associated Pruritus.
Cureus
January 2024
Nephrology, Mohammed VI University Hospital, Marrakesh, MAR.
Article Synopsis
- * Recent interest has emerged in using narrowband ultraviolet B (NB-UVB) phototherapy for CKDaP, particularly for patients who do not respond to standard treatments like emollients and antihistamines.
- * A study involving 38 dialysis patients evaluated the effects of NB-UVB treatment on their itching intensity and quality of life, using a numerical rating scale to measure improvement after sessions of UVB light therapy.
Pruritus in Pregnancy.
J Obstet Gynaecol India
February 2024
Shrikhande Hospital, Nagpur, Maharashtra India.
Article Synopsis
- Pruritus, or itching, is a common yet often overlooked symptom during pregnancy that can cause significant discomfort for expectant mothers.
- While there's plenty of research on pregnancy-specific skin conditions causing pruritus, it's crucial to consider a wider range of possible causes, including infections and systemic diseases.
- The article aims to provide a comprehensive overview of why pruritus occurs in pregnancy, how to diagnose it, and the best management practices for both the mother and fetus.
Real-world effectiveness and safety of abrocitinib in 12 Japanese patients with atopic dermatitis and transcriptome analysis with peripheral blood.
J Dermatol
June 2024
Department of Dermatology, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan.
Article Synopsis
- * In a real-world study involving 12 Japanese patients with moderate to severe AD, daily treatment with 100 mg of abrocitinib showed significant improvement in eczema severity after 4 and 12 weeks, with many patients achieving considerable reductions in Eczema Area and Severity Index (EASI) scores.
- * While abrocitinib effectively reduced pruritus and inflammation, common side effects included acne, and gene analysis indicated specific suppression of certain inflammatory pathways, suggesting its potential as a fast-acting treatment option for AD
Insights into Early Systemic Treatment in Atopic Dermatitis: Scientific Facts and Practical Considerations.
Dermatol Ther (Heidelb)
March 2024
First Department of Dermatology and Venereology, Aristotle University of Thessaloniki, Hospital of Skin and Venereal Diseases, Thessaloniki, Greece.
Article Synopsis
- * Recent research suggests that starting systemic treatments early might significantly improve AD management, potentially altering the disease's progression and improving patients' overall health outcomes.
- * By addressing itching at its source, early systemic intervention can reduce systemic inflammation, prevent complications, and lessen the mental and emotional toll of the disease, paving the way for better long-term control strategies for patients.
Multiple Eruptive Dermatofibroma: A Case Report.
Clin Cosmet Investig Dermatol
February 2024
Department of Dermatology, the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, 215006, People's Republic of China.
Article Synopsis
- Multiple eruptive dermatofibroma (MEDF) is a rare skin condition often linked to diseases like HIV or lupus, characterized by specific skin histology.
- A case study reports a 30-year-old man with a 10-year history of numerous dark brownish-red spots on his skin, diagnosed with MEDF after ruling out infections and autoimmune diseases.
- The conclusion emphasizes that MEDF typically causes no pain or itching, and if serious underlying conditions are excluded, regular check-ups are suggested instead of specific treatment.
Canine Atopic Dermatitis: Prevalence, Impact, and Management Strategies.
Vet Med (Auckl)
February 2024
College of Veterinary Medicine, Western University of Health Sciences, Pomona, CA, USA.
Article Synopsis
- Atopic dermatitis (AD) is a widespread allergic skin condition in humans and dogs that causes itching and inflammation, with increasing prevalence across species.
- The causes of AD are complex and involve genetic predispositions, skin barrier issues, changes in the microbiome, immune system problems, and allergic reactions.
- Currently, there is no cure for canine atopic dermatitis (CAD), but treatment focuses on managing symptoms, including itch control, inflammation, skin barrier repair, and proper diet.
Can Biologic Agents Improve Treatment Success in Obese Patients With Psoriasis Vulgaris: A Retrospective Review of 320 Patients With Psoriasis Vulgaris.
Dermatol Pract Concept
January 2024
Department of Dermatology, Kayseri City Education and Research Hospital, Kayseri, Turkey.
Article Synopsis
- - The study investigates how body mass index (BMI) affects treatment responses for psoriasis, highlighting obesity's role in challenging treatment outcomes.
- - Among 317 patients, obese individuals (BMI ≥30) showed lower success rates in achieving significant psoriasis improvement (PASI 75 and PASI 90) compared to non-obese patients, with biological treatments proving more effective overall.
- - Results indicate that while both IL-17 and IL-23 inhibitors are effective for obesity-related psoriasis, neither outperformed the other, and joint involvement can impact treatment success in obese patients.
Dermatological Manifestations in Patients With Chronic Kidney Disease: A Review.
Cureus
January 2024
Digital Health, Universidad Nacional Autónoma de México, Ciudad de Mexico, MEX.
Article Synopsis
- Chronic kidney disease (CKD) progresses over time, leading to various skin-related symptoms as toxin levels and inflammation increase in the body.
- Nonspecific skin issues might include itching, dry skin, and pigmentation problems, while more specific conditions could involve serious disorders like eruptive xanthoma and nephrogenic systemic fibrosis.
- Recognizing these skin changes early is crucial for improving treatment outcomes and overall patient health, as they can indicate underlying CKD complications and the need for timely intervention.
Sleep disorders and other medical and socio-demographic factors in systemic scleroderma.
Eur J Transl Myol
February 2024
Rheumatology Research Center, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran.
Article Synopsis
- - The study examined the prevalence of sleep disorders in 103 patients with systemic scleroderma (SSc) and how these disorders relate to various socio-demographic and medical factors over a period of seven months.
- - Findings indicated that a significant portion of SSc patients (68%) experienced poor sleep quality, particularly linked to skin stiffness, the presence of telangiectasia, interstitial lung disease (ILD), and various demographic factors like age and disease duration.
- - It also found that obstructive sleep apnea and insomnia were notably associated with telangiectasia, ILD, and age, suggesting the need for better disease management strategies to enhance patients' quality of life.
Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis.
Health Technol Assess
January 2024
Associate Professor in Inflammatory Skin Diseases, University of Leeds, Leeds, UK.
Article Synopsis
- Atopic dermatitis is a chronic skin condition, commonly seen in children, characterized by dry, itchy, and inflamed skin, often appearing before age 5 but can develop at any time.
- The study evaluates the clinical effectiveness and cost-effectiveness of three newer treatments—abrocitinib, tralokinumab, and upadacitinib—compared to traditional treatments like ciclosporin A and dupilumab for moderate-to-severe atopic dermatitis.
- A systematic review and network meta-analysis were conducted to analyze various treatment pathways and their outcomes, ultimately informing a new economic model for the NHS in England regarding treatment costs and effectiveness.
Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors.
J Immunother Cancer
February 2024
Legorreta Cancer Center at Brown University, Lifespan Cancer Institute, Providence, Rhode Island, USA.
Article Synopsis
- - The study explores the safety and effectiveness of combining monalizumab (anti-NKG2A) and durvalumab (anti-PD-L1) as a potential immunotherapy for patients with advanced solid tumors.
- - Conducted in two parts, it enrolled 185 patients to assess various cancers, including cervical and colorectal, using set dosages of the medications with a primary focus on safety and secondary evaluations of antitumor activity.
- - Results showed no dose-limiting toxicity and common side effects like fatigue and diarrhea; however, response rates across different cancer types were low, indicating limited effectiveness of this combination therapy.
T-cell immune profile in blood of systemic mastocytosis: Association with disease features.
Allergy
July 2024
Department of Medicine and Cytometry Service (NUCLEUS), Cancer Research Center (IBMCC, USAL-CSIC), Universidad de Salamanca, Salamanca, Spain.
Article Synopsis
- Systemic mastocytosis (SM) is a complex disease marked by an increase in abnormal mast cells that can affect the immune system and tumor environment.
- Researchers analyzed blood samples from 115 SM patients and 83 healthy individuals to assess the distribution of various immune cells and their relationship with disease characteristics.
- Findings indicated that SM patients had reduced levels of specific immune cell types compared to healthy controls, with these variations depending on the subtype of SM and certain genetic factors linked to the disease.
Dupilumab treatment improves signs, symptoms, quality of life, and work productivity in patients with atopic hand and foot dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trial.
J Am Acad Dermatol
June 2024
Regeneron Pharmaceuticals Inc, Tarrytown, New York. Electronic address:
Article Synopsis
- - The study evaluates the effectiveness and safety of dupilumab for treating atopic hand and/or foot dermatitis, a condition with few treatment options.
- - In a phase 3 trial, 133 patients received either dupilumab or a placebo, with results showing more patients on dupilumab achieved significant improvements in disease severity at week 16.
- - The findings suggest dupilumab is a promising treatment for hand and foot dermatitis, with improvements in symptoms and quality of life, although the study's short duration is a limitation.